A 5-year-old boy with a coronary cameral fistula was successfully treated using Amplatzer™ devices, emphasizing the importance of multimodal imaging and timely intervention to prevent heart failure and ischemia.

Myocarditis, an inflammatory heart condition, presents varying symptoms. Immunosuppressive therapy is debated, though effective in specific cases. Diagnosis via endomyocardial biopsy guides tailored treatment strategies.

This narrative review highlights factors influencing heart rate variability (HRV), categorizing them as non-influenceable physiological factors, diseases, lifestyle choices, and external elements, stressing the importance of considering these confounders in HRV interpretation.

Targeting gut composition may significantly improve heart failure (HF) outcomes by addressing gut dysbiosis and epithelial barrier dysfunction, highlighting a crucial therapeutic avenue.

Empagliflozin reduced HF hospitalizations post-AMI, regardless of LVEF or congestion, with consistent safety. Severity of LVEF dysfunction and congestion correlated with worse outcomes.

Despite advances in reperfusion and secondary prevention, chronic heart failure (HF) remains common post-myocardial infarction (MI). Neurohormonal inhibition and emerging therapies aim to mitigate HF risk and myocardial damage.

Heart failure (HF) treatment involves antihypertensives and other drugs, regardless of left ventricular ejection fraction (LVEF). Focus on symptom management, signs, severity, and comorbid conditions.

Heart transplantation advances include xenotransplantation, hepatitis C donors, improved rejection monitoring, and novel immunosuppressants, enhancing outcomes for patients with advanced heart failure.

HFpEF's complex pathophysiology involves both cardiac and non-cardiac factors. Improving vascular health through interventions could enhance outcomes, underscoring the need for an integrative approach to treatment.

Fluid retention in heart failure (HF) is managed primarily with loop diuretics, needing updated research to optimize treatment strategies and improve guidelines.

HFpEF is a complex heart failure syndrome with limited drug therapies. Emerging device-based therapies show promise in improving symptoms and reducing readmissions.

Guideline-directed medical therapy for heart failure may influence cancer incidence and outcomes. Future research should refine HF treatment strategies in the context of coexisting cancer.

Antiarrhythmic therapy in HF requires a systematic, multimodal approach, integrating pharmacological, device, and interventional therapy for optimal outcomes.

There is a paucity of evidence around educational interventions to support residents living with heart failure in nursing homes. However, available evidence suggests that educational interventions in nursing homes may improve care through improving staff self-efficacy and confidence in providing care, heart failure knowledge and...

Understand and address heart failure with preserved ejection fraction (HFpEF), highlighting its complex mechanisms and the urgency for early recognition and treatment to mitigate its progression and impact, particularly given its increasing prevalence in an aging population.

Achieving complete decongestion remains the primary therapeutic objective during hospitalization for heart failure, with early initiation and titration of quadruple therapy recommended to prevent readmissions for heart failure with reduced ejection fraction.

Understanding the role of inflammasomes in heart failure (HF) pathophysiology reveals their potential as biomarkers and therapeutic targets. Modulating inflammasome signaling could offer innovative strategies for managing HF.

Empagliflozin reduced the risk of HF in patients with left ventricular dysfunction or congestion after acute myocardial infarction.

Recent updates in heart failure management highlight significant advances such as the use of SGLT2 inhibitors and finerenone for prevention in diabetic CKD, and expanded treatments across HF spectrums. Emerging therapies like vericiguat and semaglutide show promise, while ongoing research continues to refine treatment strategies.